Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, clorhidrat de metformină - diabetul zaharat, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 și 5. 1 pentru datele disponibile pe diferite combinații).

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - miotonice tulburări - terapia cardiacă - namuscla este indicat pentru tratamentul simptomatic al miotonie la pacienții adulți cu non-distrofice miotonice tulburări.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

ceva santé animale - benazepril hydrochloride, spironolactone - sistemul cardiovascular - câini - pentru tratamentul insuficienței cardiace congestive cauzate de boala cronică degenerativă cronică la câini (cu suport diuretic, după caz).

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetul zaharat, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psihoterapie, hipnotice și sedative - câini - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Moldova - Tiếng Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

seacross pharmaceuticals limited - irinotecanum - concentrat pentru soluţie perfuzabilă - 20 mg/ml

Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z.o.o. - polonia - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/1000mg - analogi ai glp-1 combinatii de antidiabetice orale

Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z.o.o. - polonia - combinatii (sitagliptinum+metforminum) - compr. film. - 50mg/850mg - analogi ai glp-1 combinatii de antidiabetice orale

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - diclorhidrat de sapropterină - phenylketonurias - alte medicamente pentru tractul digestiv și metabolism, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenți antineoplazici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.